50,096 Shares in Axsome Therapeutics, Inc. (NASDAQ:AXSM) Bought by Universal Beteiligungs und Servicegesellschaft mbH

Key Points

• Universal Beteiligungs und Servicegesellschaft mbH acquired 50,096 shares of Axsome Therapeutics, valued at approximately $5.84 million, during the first quarter, holding about 0.10% of the company after the investment.
• Insider transactions revealed significant sales, including COO Mark L. Jacobson selling 25,000 shares for around $2.76 million and a total of 93,437 shares sold by insiders valued at nearly $9.83 million over three months.
• Analysts have a consensus rating of "Buy" for Axsome Therapeutics, with price targets ranging from $160 to $200 following recent ratings upgrades.

Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 50,096 shares of the company's stock, valued at approximately $5,843,000. Universal Beteiligungs und Servicegesellschaft mbH owned 0.10% of Axsome Therapeutics as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also modified their holdings of the company. NBC Securities Inc. purchased a new position in shares of Axsome Therapeutics in the 1st quarter valued at $31,000. Raiffeisen Bank International AG acquired a new stake in Axsome Therapeutics during the 4th quarter valued at $51,000. Aquatic Capital Management LLC acquired a new stake in Axsome Therapeutics during the 4th quarter valued at $76,000. GF Fund Management CO. LTD. acquired a new stake in Axsome Therapeutics during the 4th quarter valued at $86,000. Finally, Bank Hapoalim BM acquired a new position in Axsome Therapeutics during the 1st quarter worth $204,000. Hedge funds and other institutional investors own 81.49% of the company's stock.

Insider Activity

In related news, General Counsel Hunter R. Murdock sold 6,014 shares of the company's stock in a transaction that occurred on Monday, June 23rd. The stock was sold at an average price of $100.12, for a total value of $602,121.68. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Mark Coleman sold 3,750 shares of the company's stock in a transaction that occurred on Tuesday, May 27th. The shares were sold at an average price of $105.47, for a total value of $395,512.50. Following the completion of the sale, the director owned 50,387 shares in the company, valued at $5,314,316.89. The trade was a 6.93% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 93,437 shares of company stock valued at $9,834,215. 22.40% of the stock is currently owned by corporate insiders.

Axsome Therapeutics Stock Performance

Shares of AXSM traded down $0.44 during midday trading on Monday, reaching $100.39. 699,715 shares of the stock were exchanged, compared to its average volume of 590,439. The company has a quick ratio of 1.96, a current ratio of 2.03 and a debt-to-equity ratio of 3.48. Axsome Therapeutics, Inc. has a twelve month low of $72.21 and a twelve month high of $139.13. The company has a market cap of $4.94 billion, a P/E ratio of -17.40 and a beta of 0.46. The stock's 50 day simple moving average is $106.35 and its 200 day simple moving average is $110.19.

Analyst Ratings Changes

A number of research analysts have recently issued reports on AXSM shares. HC Wainwright restated a "buy" rating and issued a $180.00 price target on shares of Axsome Therapeutics in a research report on Tuesday, June 10th. Oppenheimer began coverage on shares of Axsome Therapeutics in a research report on Tuesday, June 3rd. They issued an "outperform" rating and a $185.00 price objective on the stock. Cantor Fitzgerald upgraded shares of Axsome Therapeutics to a "strong-buy" rating in a research report on Wednesday, May 14th. Robert W. Baird lifted their price objective on shares of Axsome Therapeutics from $160.00 to $162.00 and gave the company an "outperform" rating in a research report on Tuesday, May 6th. Finally, Wells Fargo & Company reiterated an "overweight" rating and issued a $165.00 price objective (up from $160.00) on shares of Axsome Therapeutics in a research report on Tuesday, May 6th. One investment analyst has rated the stock with a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus price target of $172.33.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.